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Volume 54, Number 2 Abstracts 583ventricular contractility or anti- arrhythmic properties of -blockers.
-blockers may also prevent plaque rupture in coronary arteries by reducing
mechanical stress on the coronary plaques (Lopez-Sendon J, et.al. Eur
Heart J 2004:25:1341-62) and may decrease circulating levels of C-reactive
protein thereby stabilizing coronary plaques through anti inflammatory
mechanisms (Jenkins NP, et.al. Am JMed 2002;112:269-74). The duration
of -blocker treatment before vascular surgery and its effect on cardiovas-
cular outcome in vascular surgical patients has not, however, been specifi-
cally studied. The authors sought to evaluate the timing of -blocker
initiation and its influence on preoperative heart rate, C-reactive protein
levels, and post operative outcome in a cohort of patients undergoing
vascular surgery.
Preoperative heart rate and high sensitive C-reactive protein (CRP)
levels were recorded in 940 vascular surgical patients with respect to time of
the -blocker initiation before surgery. Initiation of -blocker’s was divided
into three time periods, 1 week prior to surgery, 1-4 weeks prior to
surgery, and 4 weeks prior to surgery. Troponin- T measurements were
made pre and post operatively and electrocardiograms were also routinely
obtained. The endpoints of the study included 30 day cardiac events (a
composite of myocardial infarction and cardiac mortality) as well as long
term mortality. The relationship between duration of -blocker treatment
and outcome was evaluated by multi-variant regression analysis adjusted to
cardiac risk factors.
There were 158 patients (17%) who had -blockers initiated 1 week
prior to vascular surgery. There were 393 patients (42%) who had -blocker
therapy initiated between 1 and 4 weeks prior to vascular surgery and 389
patients (41%) who had -blocker therapy more than 4 weeks prior to
vascular surgery. In comparing heart-rates of new patients with -blocker
therapy initiated  1 week preoperatively to those patients where therapy
was initiated 1 week preoperatively there was a significant decrease in
median heart rate in the patients with therapy initiated 1 week preopera-
tively (74  17 beats/min versus 66  15 beats/min; P  0.001). Median
CRP levels were not different in patients in which -blocker therapy was
initiated 1 week preoperatively compared to patients in which -blocker
therapy was initiated1 week preoperatively (P .782). There was a lower
incidence of 30 day cardiac events in patients in which -blocker therapy was
initiated 1 week to 4 weeks or 4 weeks prior to surgery compared to
those where therapy was initiated  1 week prior to vascular surgery (OR,
0.46; 95% CI, 0.27-0.76; OR, 0.48; 95% CI, 0.29-0.79). There was also
improved long term mortality in patients with -blocker therapy initiated
between 1 and 4 weeks and4 weeks preoperatively compared to those with
therapy initiated1 week preoperatively (HR, 0.52; 95% CI, 021-0.67; and
HR, 0.50; 95% CI, 0.25-0.71, respectively). There were there perioperative
strokes in the patients in whom -blocker therapy was initiated 1 week
preoperatively versus 4 perioperative strokes in the patients where -blocker
therapy was initiated more than 1 week preoperatively (P  .021).
Comment: There appear to be significant advantages to initiating
-blocker therapy more than 1 week preoperatively in patients undergoing
vascular surgery. A number of questions do remain. Could one prescribe
higher -blocker doses to achieve more rapid heart rate control and then be
able to routinely start treatment 1 week preoperatively? Or, will more
aggressive up titration of -blocker therapy perhaps lead to potential over-
dosing of the drug and more side effects? Indeed, the POSIE trial suggested
that higher -blocker doses without up -titration in surgical patients can lead
to an increased incidence of bradycardia, hypertension and stroke. Clearly,
trying to initiate -blocker therapy with monitoring and up titration
of therapy in less than a week would poses logistical difficulties. Another
question is whether to use perioperative -blockers in -blocker naïve
d
watients who require urgent vascular surgery? What this trial tells us is that in
lective cases of vascular surgery one should start -blockers more than one
eek prior to surgery. What to do with -blocker naïve patients who require
rgent operation remains an open question as does how rapidly can -block-
rs be safely introduced to the preoperative vascular surgery patient.
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4.
Conclusion: Women with peripheral arterial disease (PAD) have
reater loss of mobility and faster functional decline than men with PAD.
ifferences may be attributable to women with PAD having smaller baseline
alf muscle area than men with PAD.
Summary: The prevalence of PAD in older patients is the same in
omen as in men and may be higher (Vavra AK. Women’s Health 2009;5:
69-83). It has been demonstrated women with PAD have decreased lower
xtremity strength and greater functional impairment than men with PAD
McDermott MM. J Am Geriatric Soc 2003;51:222-8). In this study the
uthors determined whether there are sex differences in rate of functional
ecline over time and whether there are differences in rates of change of calf
uscles characteristics over time between men and women with PAD.
This was a longitudinal observational study. Rates of mobility loss,
ecline in six minute walk performance, and decline in walking velocity
etween men and women with PAD were determined at baseline and at 4
ears of follow up. Baseline measurements of calf muscle characteristics and
eg strength and changes in these muscle parameters between women and
en with PAD were also determined at baseline and at 4 years of follow up.
here were 380 men and women with PAD who completed a six minute
alk test and were assessed for mobility, disability, and who underwent an
valuation of 4 meter walking velocity at baseline and annually for up to 4
ears. Calf muscle characteristics were measured biannually with computed
omography. Outcomes included becoming unable to walk for 6 minutes
ontinuously among patients who could walk continuously for 6 minutes at
aseline. An additional outcome was mobility loss defined as becoming
nable to walk for one-quarter mile or to walk up and down one flight of
tairs without assistance. Adjustments were made for race, age, body mass
ndex, the ankle brachial index, physical activity, comorbidities, and other
onfounders.
At 4 years of follow-up, women were more likely to become unable to
alk for 6 minutes continuously (HR, 2.3; 95%CI, 1.3-4.06; P  .004).
omen were more likely to develop mobility disability (HR, 1.79; 95% CI,
.3-3.03; P .03). Women also had faster declines in walking velocity (P
022) and distance achieved during the 6 minute walk (P  .041). After
djustment for a baseline sex differences in calf muscle area sex differences in
unctional decline were no longer statically significant.
Comment: In this study women had smaller calf muscle area and lower
alf muscle densities and less knee extension strength at baseline compared
o men. With adjustments in the analysis sex differences in functional decline
etween women and men with PAD disappeared. This suggests poorer
unctional performance at baseline among women compared to men results
n women being closer at baseline to thresholds for mobility loss and physical
ysfunction. Interventions to improve lower extremity strength among
omen with PAD may slow their functional decline.
